A FcγRIII-engaging bispecific antibody expands the range of HER2-expressing breast tumors eligible to antibody therapy

Oncotarget

Volumn 5, Issue 14, 2014, Pages 5304-5319

  Turini, Marc ^a,b,c,d   Chames, Patrick ^a,b,c,d   Bruhns, Pierre ^e,f   Baty, Daniel ^a,b,c,d   Kerfelec, Brigitte ^a,b,c,d  

^a AIX MARSEILLE UNIVERSITY   (France)

^b INSTITUT PAOLI CALMETTES   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

^d CNRS   (France)

^e INSTITUT PASTEUR   (France)

^f INSERM   (France)

Author keywords

Bispecific antibody; Breast cancer; Fc RIIIA polymorphism; HER2; Trastuzumab

Indexed keywords

ANTINEOPLASTIC AGENT; CD16 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2 BISPECIFIC FAB ANTIBODY; FC RECEPTOR; FC RECEPTOR I; FC RECEPTOR IIB; FC RECEPTOR IV; GAMMA INTERFERON; GRANZYME B; IMMUNOGLOBULIN F(AB) FRAGMENT; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PROTEIN KINASE B; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; BISPECIFIC ANTIBODY; ERBB2 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY AFFINITY; ANTIBODY COMBINING SITE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY STRUCTURE; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; HER2 EXPRESSING BREAST CANCER; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE ACTIVATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PROTEIN POLYMORPHISM; ANIMAL; BIOSYNTHESIS; BREAST NEOPLASMS; DRUG SCREENING; ENZYMOLOGY; FEMALE; IMMUNOLOGY; JURKAT CELL LINE; NUDE MOUSE; RANDOMIZATION; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; JURKAT CELLS; KILLER CELLS, NATURAL; MICE; MICE, NUDE; RANDOM ALLOCATION; RECEPTOR, ERBB-2; RECEPTORS, IGG; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84906241263     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2093     Document Type: Article

References (61)

1. Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology. 2001; 61 Suppl 2:1-13.
2. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ and Press M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002; 20(3):719-726.
3. Slamon D and Pegram M. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol. 2001; 28(1 Suppl 3):13-19.
4. Rodrigues MJ, Wassermann J, Albiges L, Brain E, Delaloge S, Stevens D, Guinebretiere JM, Mathieu MC, Kirova Y, Guillot E, Vincent-Salomon A and Cottu PH. Trastuzumab treatment in t1ab, node-negative, human epidermal growth factor receptor 2-overexpressing breast carcinomas. J Clin Oncol. 2010; 28(28):e541-542.
5. Kruser TJ and Wheeler DL. Mechanisms of resistance to HER family targeting antibodies. Exp Cell Res. 2010; 316(7):1083-1100.
6. Nahta R and Esteva FJ. Herceptin: mechanisms of action and resistance. Cancer Lett. 2006; 232(2):123-138.
7. Valabrega G, Montemurro F and Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol. 2007; 18(6):977-984.
8. Spiridon CI, Guinn S and Vitetta ES. A comparison of the in vitro and in vivo activities of IgG and F(ab')2 fragments of a mixture of three monoclonal anti-Her-2 antibodies. Clin Cancer Res. 2004; 10(10):3542-3551.
9. Clynes RA, Towers TL, Presta LG and Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000; 6(4):443-446.
10. Albanesi M, Mancardi DA, Jonsson F, Iannascoli B, Fiette L, Di Santo JP, Lowell CA and Bruhns P. Neutrophils mediate antibody-induced antitumor effects in mice. Blood. 2013; 122(18):3160-3164.
11. Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, Cabaret V, Fermeaux V, Bertheau P, Garnier J, Jeannin JF and Coudert B. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer. 2006; 94(2):259-267.
12. Varchetta S, Gibelli N, Oliviero B, Nardini E, Gennari R, Gatti G, Silva LS, Villani L, Tagliabue E, Menard S, Costa A and Fagnoni FF. Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Res. 2007; 67(24):11991-11999.
13. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, Laccabue D, Zerbini A, Camisa R, Bisagni G, Neri TM and Ardizzoni A. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol. 2008; 26(11):1789-1796.
14. Park S, Jiang Z, Mortenson ED, Deng L, Radkevich-Brown O, Yang X, Sattar H, Wang Y, Brown NK, Greene M, Liu Y, Tang J, Wang S and Fu YX. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell. 2010; 18(2):160-170.
15. Junttila TT, Parsons K, Olsson C, Lu Y, Xin Y, Theriault J, Crocker L, Pabonan O, Baginski T, Meng G, Totpal K, Kelley RF and Sliwkowski MX. Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer. Cancer Res. 2010; 70(11):4481-4489.
16. Nordstrom JL, Gorlatov S, Zhang W, Yang Y, Huang L, Burke S, Li H, Ciccarone V, Zhang T, Stavenhagen J, Koenig S, Stewart SJ, Moore PA, Johnson S and Bonvini E. Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcgamma receptor binding properties. Breast Cancer Res. 2011; 13(6):R123.
17. Jaime-Ramirez AC, Mundy-Bosse BL, Kondadasula S, Jones NB, Roda JM, Mani A, Parihar R, Karpa V, Papenfuss TL, LaPerle KM, Biller E, Lehman A, Chaudhury AR, Jarjoura D, Burry RW and Carson WE, 3rd. IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-gamma production. J Immunol. 2011; 186(6):3401-3409.
18. Welslau M, Dieras V, Sohn JH, Hurvitz SA, Lalla D, Fang L, Althaus B, Guardino E and Miles D. Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer. Cancer. 2013.
19. Lewis Phillips GD, Fields CT, Li G, Dowbenko D, Schaefer G, Miller KD, Andre F, Burris HA, 3rd, Albain KS, Harbeck N, Dieras V, Crivellari D, Fang L, Guardino E, Olsen SR, Crocker LM, et al. Dual targeting of HER2-positive cancer with trastuzumab-emtansine (T-DM1) and pertuzumab: critical role for neuregulin blockade in anti-tumor response to combination therapy. Clin Cancer Res. 2013; 15:456-468.
20. Diermeier-Daucher S, Ortmann O, Buchholz S and Brockhoff G. Trifunctional antibody ertumaxomab: Non-immunological effects on Her2 receptor activity and downstream signaling. MAbs. 2012; 4(5):614-622.
21. Chames P and Baty D. Bispecific antibodies for cancer therapy: the light at the end of the tunnel? MAbs. 2009; 1(6):539-547.
22. Kontermann R. Dual targeting strategies with bispecific antibodies. MAbs. 2012; 4(2):182-197.
23. Topp MS, Gokbuget N, Zugmaier G, Degenhard E, Goebeler ME, Klinger M, Neumann SA, Horst HA, Raff T, Viardot A, Stelljes M, Schaich M, Kohne-Volland R, Bruggemann M, Ottmann OG, Burmeister T, et al. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood. 2012; 120(26):5185-5187.
24. Linke R, Klein A and Seimetz D. Catumaxomab: clinical development and future directions. MAbs. 2010; 2(2):129-136.
25. Frankel SR and Baeuerle PA. Targeting T cells to tumor cells using bispecific antibodies. Curr Opin Chem Biol. 2013; 17(3):385-392.
26. Bruhns P. Properties of mouse and human IgG receptors and their contribution to disease models. Blood. 2012; 119(24):5640-5649.
27. Weiskopf K, Ring AM, Schnorr PJ, Volkmer JP, Volkmer AK, Weissman IL and Garcia KC. Improving macrophage responses to therapeutic antibodies by molecular engineering of SIRPalpha variants. Oncoimmunology. 2013; 2(9):e25773.
28. Thakur A and Lum LG. Cancer therapy with bispecific antibodies: Clinical experience. Curr Opin Mol Ther. 2010; 12(3):340-349.
29. Reusch U, Burkhardt C, Fucek I, Le Gall F, Le Gall M, Hoffmann K, Knackmuss SH, Kiprijanov S, Little M and Zhukovsky EA. A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells. MAbs. 2014; 6(3):728-739.
30. Rozan C, Cornillon A, Petiard C, Chartier M, Behar G, Boix C, Kerfelec B, Robert B, Pelegrin A, Chames P, Teillaud JL and Baty D. Single-domain antibody-based and linker-free bispecific antibodies targeting FcgammaRIII induce potent antitumor activity without recruiting regulatory T cells. Mol Cancer Ther. 2013; 12(8):1481-1491.
31. Behar G, Siberil S, Groulet A, Chames P, Pugniere M, Boix C, Sautes-Fridman C, Teillaud JL and Baty D. Isolation and characterization of anti-FcgammaRIII (CD16) llama single-domain antibodies that activate natural killer cells. Protein Eng Des Sel. 2008; 21(1):1-10.
32. Tanner M, Kapanen AI, Junttila T, Raheem O, Grenman S, Elo J, Elenius K and Isola J. Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. Mol Cancer Ther. 2004; 3(12):1585-1592.
33. Nagy P, Friedlander E, Tanner M, Kapanen AI, Carraway KL, Isola J and Jovin TM. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res. 2005; 65(2):473-482.
34. Lacroix M and Leclercq G. Relevance of breast cancer cell lines as models for breast tumours: an update. Breast Cancer Res Treat. 2004; 83(3):249-289.
35. Preithner S, Elm S, Lippold S, Locher M, Wolf A, da Silva AJ, Baeuerle PA and Prang NS. High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G. Mol Immunol. 2006; 43(8):1183-1193.
36. Shields RL, Namenuk AK, Hong K, Meng YG, Rae J, Briggs J, Xie D, Lai J, Stadlen A, Li B, Fox JA and Presta LG. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem. 2001; 276(9):6591-6604.
37. Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, Weikert SH and Presta LG. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem. 2002; 277(30):26733-26740.
38. Lazar GA, Dang W, Karki S, Vafa O, Peng JS, Hyun L, Chan C, Chung HS, Eivazi A, Yoder SC, Vielmetter J, Carmichael DF, Hayes RJ and Dahiyat BI. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci U S A. 2006; 103(11):4005-4010.
39. Keler T, Graziano RF, Mandal A, Wallace PK, Fisher J, Guyre PM, Fanger MW and Deo YM. Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fc gamma receptor type I-expressing effector cells. Cancer Res. 1997; 57(18):4008-4014.
40. Wozniak-Knopp G, Bartl S, Bauer A, Mostageer M, Woisetschlager M, Antes B, Ettl K, Kainer M, Weberhofer G, Wiederkum S, Himmler G, Mudde GC and Ruker F. Introducing antigen-binding sites in structural loops of immunoglobulin constant domains: Fc fragments with engineered HER2/neu-binding sites and antibody properties. Protein Eng Des Sel. 2010; 23(4):289-297.
41. Grabert RC, Cousens LP, Smith JA, Olson S, Gall J, Young WB, Davol PA and Lum LG. Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation. Clin Cancer Res. 2006; 12(2):569-576.
42. Jager M, Schoberth A, Ruf P, Hess J and Lindhofer H. The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2. Cancer Res. 2009; 69(10):4270-4276.
43. Borghaei H, Alpaugh RK, Bernardo P, Palazzo IE, Dutcher JP, Venkatraj U, Wood WC, Goldstein L and Weiner LM. Induction of adaptive Anti-HER2/neu immune responses in a Phase 1B/2 trial of 2B1 bispecific murine monoclonal antibody in metastatic breast cancer (E3194): a trial coordinated by the Eastern Cooperative Oncology Group. J Immunother. 2007; 30(4):455-467.
44. Weiner LM, Holmes M, Adams GP, LaCreta F, Watts P and Garcia de Palazzo I. A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16. Cancer Res. 1993; 53(1):94-100.
45. Even-Desrumeaux K, Fourquet P, Secq V, Baty D and Chames P. Single-domain antibodies: a versatile and rich source of binders for breast cancer diagnostic approaches. Mol Biosyst. 2012; 8(9):2385-2394.
46. Rudnick SI, Lou J, Shaller CC, Tang Y, Klein-Szanto AJ, Weiner LM, Marks JD and Adams GP. Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors. Cancer Res. 2011; 71(6):2250-2259.
47. Adams GP, Schier R, McCall AM, Simmons HH, Horak EM, Alpaugh RK, Marks JD and Weiner LM. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res. 2001; 61(12):4750-4755.
48. Cao Y, Marks JD, Huang Q, Rudnick SI, Xiong C, Hittelman WN, Wen X, Marks JW, Cheung LH, Boland K, Li C, Adams GP and Rosenblum MG. Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicity. Mol Cancer Ther. 2012; 11(1):143-153.
49. Overdijk MB, Verploegen S, van den Brakel JH, Lammerts van Bueren JJ, Vink T, van de Winkel JG, Parren PW and Bleeker WK. Epidermal growth factor receptor (EGFR) antibody-induced antibody-dependent cellular cytotoxicity plays a prominent role in inhibiting tumorigenesis, even of tumor cells insensitive to EGFR signaling inhibition. J Immunol. 2011; 187(6):3383-3390.
50. Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM and Moasser MM. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature. 2007; 445(7126):437-441.
51. Nahta R, Yuan LX, Zhang B, Kobayashi R and Esteva FJ. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res. 2005; 65(23):11118-11128.
52. Weiner LM, Alpaugh RK, Amoroso AR, Adams GP, Ring DB and Barth MW. Human neutrophil interactions of a bispecific monoclonal antibody targeting tumor and human Fc gamma RIII. Cancer Immunol Immunother. 1996; 42(3):141-150.
53. Fauriat C, Long EO, Ljunggren HG and Bryceson YT. Regulation of human NK-cell cytokine and chemokine production by target cell recognition. Blood. 2010; 115(11):2167-2176.
54. Damiano V, Garofalo S, Rosa R, Bianco R, Caputo R, Gelardi T, Merola G, Racioppi L, Garbi C, Kandimalla ER, Agrawal S and Tortora G. A novel toll-like receptor 9 agonist cooperates with trastuzumab in trastuzumab-resistant breast tumors through multiple mechanisms of action. Clin Cancer Res. 2009; 15(22):6921-6930.
55. Osborne CK, Hobbs K and Trent JM. Biological differences among MCF-7 human breast cancer cell lines from different laboratories. Breast Cancer Res Treat. 1987; 9(2):111-121.
56. Barok M, Isola J, Palyi-Krekk Z, Nagy P, Juhasz I, Vereb G, Kauraniemi P, Kapanen A, Tanner M and Szollosi J. Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol Cancer Ther. 2007; 6(7):2065-2072.
57. Baselga J, Gelmon KA, Verma S, Wardley A, Conte P, Miles D, Bianchi G, Cortes J, McNally VA, Ross GA, Fumoleau P and Gianni L. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol. 2010; 28(7):1138-1144.
58. Cortes J, Fumoleau P, Bianchi GV, Petrella TM, Gelmon K, Pivot X, Verma S, Albanell J, Conte P, Lluch A, Salvagni S, Servent V, Gianni L, Scaltriti M, Ross GA, Dixon J, et al. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2012; 30(14):1594-1600.
59. Even-Desrumeaux K and Chames P. Affinity determination of biotinylated antibodies by flow cytometry. Methods Mol Biol. 2012; 907:443-449.
60. Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S and Daeron M. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood. 2009; 113(16):3716-3725.
61. Mancardi DA, Iannascoli B, Hoos S, England P, Daeron M and Bruhns P. FcgammaRIV is a mouse IgE receptor that resembles macrophage FcepsilonRI in humans and promotes IgE-induced lung inflammation. J Clin Invest. 2008; 118(11):3738-3750.